depewjapan.com↗
徳普化学株式会社|Depew Japan
中国に特化した、医薬品原薬・中間体、ファインケミカル、健康食品・化粧品原料の専門商社です。 【徳普化学株式会社】MF国内管理人業務・各薬事対応は、現地メーカーと直接行っております。
| Website | depewjapan.com ↗ |
| Site language | Japanese |
| Last read | 2 Oct 2026 |
Sites ranked next to it
| Rank | Site | Description | Technologies | Language |
|---|---|---|---|---|
| 16288901 | Crossignal Therapeutics is developing new generation of small molecule anti cancer immunotherapies. Get in touch with us today. | Apache HTTP Server | English | |
| 16288902 | Home | Azure Edge NetworkApache HTTP Server+1 | ||
| 16288903 | Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026. | HSTSNetlify+1 | English | |
| Ad | Serpex Search APIserpex.dev | The fast, affordable search API for AI & data projects. | Google AnalyticsNext.js | English |
| 16288904 | DeepStart Ventures is an operator-led, AI-native venture studio and early-stage investor. We turn founder insight, overlooked technology, breakthrough research, and hard market problems into AI-native products and companies. | HSTSVercel+1 | English | |
| 16288906 | Directed Energy Therapeutics | HTTP/3Firebase+1+2 | English | |
| 16288907 | EdgeOne Venture Partners builds and operationalizes device-dependent therapeutic ventures, validated in EdgeOne Medical's FDA-inspected, ISO 13485-certified labs. | Google AnalyticsGoogle Tag Manager+7+8 | English | |
| 16288908 | eRIC SOLUTIONS delivers CTMS, EDC, data management, pharmacovigilance, and clinical research solutions for pharma, biotech, and CROs. | HTTP/3Next.js+6+7 | English | |
| 16288909 | Seed-stage biotech investments and strategic advisory: financing, business planning, partnerships, licensing and M&A for breakthrough therapeutics. | HSTSVercel+1 | English | |
| 16288910 | We're not afraid of things that are different. | GoDaddy Website BuilderHSTS+1 | American English |
Is this your site? Request removal of the depewjapan.com page.
